1. Home
  2. DCOY vs ARTL Comparison

DCOY vs ARTL Comparison

Compare DCOY & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DCOY

Decoy Therapeutics Inc. Common Stock

N/A

Current Price

$6.07

Market Cap

4.2M

Sector

Health Care

ML Signal

N/A

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$1.26

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCOY
ARTL
Founded
N/A
2011
Country
United States
United States
Employees
11
7
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2M
4.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DCOY
ARTL
Price
$6.07
$1.26
Analyst Decision
Strong Buy
Hold
Analyst Count
1
2
Target Price
$30.00
N/A
AVG Volume (30 Days)
13.9K
874.6K
Earning Date
05-16-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$1.05
52 Week High
$9.57
$28.60

Technical Indicators

Market Signals
Indicator
DCOY
ARTL
Relative Strength Index (RSI) 47.08 32.26
Support Level $4.98 $1.22
Resistance Level $6.47 $1.87
Average True Range (ATR) 0.88 0.09
MACD -0.16 0.09
Stochastic Oscillator 22.39 17.67

Price Performance

Historical Comparison
DCOY
ARTL

About DCOY Decoy Therapeutics Inc. Common Stock

Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: